| Literature DB >> 35310030 |
Mohammad Amin Khazeei Tabari1,2, Razie Mirjalili1,2, Hooman Khoshhal1,2, Elahe Shokouh1,2, Mohanna Khandan1,2, Elham Hasheminasabgorji3, Ali Hafezi-Moghadam4,5, Abouzar Bagheri3.
Abstract
Background and Purpose. Diabetes mellitus (DM), hyperglycemia, and hypertension can result in diabetic retinopathy (DR), which is a major cause of blindness on a global scale. Development of DR is associated with decreased endothelial cells, increased basal membrane thickness, permeation of the retinal blood barrier, and neovascularization in patients. The purpose of the present review is to provide an overview of the findings regarding applications of phytochemicals for DR treatment and could be a beneficial resource for further clinical studies and also a basis for pharmaceutical purposes for drug design. Materials and Methods. A narrative literature review was performed from electronic databases including Web of Science, PubMed, and Scopus to analyze the effects of different phytochemicals to prevent or treat oxidation, angiogenesis, and inflammation in diabetic retinopathy. The inclusion criteria were original studies, which included the effects of different phytochemicals on diabetic retinopathy. The exclusion criteria included studies other than original articles, studies which assessed the effects of phytochemicals on nondiabetic retinopathy, and studies which used phytochemical-rich extracts. Results and Conclusions. Studies have shown that increased levels of inflammatory cytokines, angiogenic, and oxidative stress factors are involved in the progression and pathogenesis of DR. Therefore, phytochemicals with their anti-inflammatory, antiangiogenic, and antioxidant properties can prevent DR progression and retinal damage through various cellular mechanisms. It is also shown that some phytochemicals can simultaneously affect the inflammation, oxidation, and angiogenesis in DR.Entities:
Year: 2022 PMID: 35310030 PMCID: PMC8926515 DOI: 10.1155/2022/4708527
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Chemical structures of different phytochemicals used for diabetic retinopathy treatment.
|
|
|
|
|
|
| Aloe-emodin | Andrographolide | Biochanin | Hesperetin | Hesperidin |
|
|
|
|
|
|
| Decursin | Scutellarin | Sinomenine | Silybin | Genistein |
|
|
|
|
|
|
| Andrographolide | Lithospermic acid B | Alpha-mangostin | Formononetin | Pterostilbene |
|
|
|
|
|
|
| Kaempferol | Naringin | Chlorogenic acid | Taxifolin | Chrysin |
|
|
|
|
|
|
| Eriodictyol | Curcumin | Anthocyanin | Gentiopicroside | Chebulagic acid |
|
|
|
|
|
|
| Chebulinic acid | Gallic acid |
| Docosahexaenoic acid | Shikonin |
|
|
|
|
|
|
| Resveratrol | Gastrodin | Sauchinone | Physcion 8-O- | Quercetin |
|
|
|
|
|
|
| Curcumolide | Sulforaphane | Baicalein | Zerumbone | Sesamin |
Effects of different phytochemicals on diabetic retinopathy pathogenesis.
| Phytochemical | Plant | Model | Dose/concentration | Study type | Mechanism | Reference |
|---|---|---|---|---|---|---|
| Aloe-emodin | — | ARPE-19 under hypoxia condition and OIR model rats | 0.2–5.0 | In vivo and in vitro | ↓ Retinal neovascularization and expressions of VEGFA, HIF-1 | Wu, 2016 |
| Alpha-mangostin |
| STZ-induced DR SD rat | 200 mg/kg/day | In vivo | ↓ MDA, AGE, RAGE, TNF- | Jariyapongskul, 2015 |
| Andrographolide |
| STZ-induced NPDR and PDR C57BL/6 mice | 10 mg/kg/day (intraperitoneally) | In vivo | ↓ Retinal angiogenesis, inflammation, breakdown of BRB, VEGF, NF- | Yu, 2015 |
| Baicalein | — | STZ-induced DR SD female rats | 150 mg/kg/d orally | In vivo | ↓ Retinal inflammation, GFAP, VEGF, IL-18, TNF-a, IL-1, vascular abnormality, loss of ganglion cell layer (GCL), and microglial activation | Yang, 2009 |
| Biochanin | — | STZ-induced DR Wistar rats | 10 and 15 mg/kg/day (orally) | In vivo | ↓ Retinal angiogenesis, inflammation, VEGF, TNF- | Mehrabadi, 2018 |
| Blueberry anthocyanins |
| High glucose-induced HRCECs | 10 | In vitro | ↓ Retinal inflammation, oxidative stress, ROS, and VEGF production ↑ CAT and SOD activity BAE, Mv, and Mv-3-gal ↓ Nox4 protein expression BAE, Mv-3-glc, and Mv-3-gal ↓ Akt expression, Mv Mv-3-glc, and Mv-3-gal ↓ ICAM-1 levels and NF- | Huang, 2018 |
| Chebulagic acid (CA), chebulinic acid (CI), and gallic acid (GA) | — | RF/6A cells were stimulated with TNF- | 1.0 to 100 | In vivo and in vitro | ↓ CA, CI, and GA: retinal angiogenesis, inflammation, expression of MMP-9, IL-6, IL8, MCP-1, phosphorylation of p38, ERK and NF- | Shanmuga, 2018 |
| Chlorogenic acid | — | STZ-induced PDR C57BL/6 mice, HRECs, RF/6A cells, and microglia BV-2 cells | 1,10 mg/kg/day (oral); 0.3125–0.5 | In vivo and in vitro | ↓ Retinal angiogenesis, microglia cell activation, VEGF expression, phosphorylation of VEGFR-2, MEK1/2, ERK1/2, and p38 | Mei, 2018 |
| Chrysin | — | HRMVEC and adult male db/db mice C57BLKS | 1–20 | In vitro and in vivo | ↑ VE-cadherin, ZO-1 junction proteins, and PECAM-1 ↓ HIF-1 | Kang, 2016 |
| Chrysin | — | HRPE cell db/db mice | 1–20 | In vivo and in vitro | ↓ Retinal neovascularization, VEGF, IGF-1, AGE secretion, RAGE, and ER stress ↑ Retinal thickness, PEDF, RPE65, LRAT, and RDH5 level | Kang, 2018 |
| Curcumin | — | STZ-induced DR Lewis rats | 0.5 g/kg, powdered diet | In vivo | ↓ Retinal inflammation, 8-OHdG, nitrotyrosine, IL-1 | Kowluru, 2007 |
| Curcumin | — | STZ-induced DR male Wistar albino rats | 1g/kg body weight of rat orally | In vivo | ↓ Retinal inflammation, HbA1c level, vessel diameter, thickening of BM, TNF-a, and VEGF ↑ GSH, SOD, and CAT activities | Suresh,2011 |
| Curcumin | — | STZ-induced DR and rat retinal Müller cells | 100 mg/kg/day (oral); 5–15 | In vivo and in vitro | ↓ Retinal vascular leakage, inflammation, VEGF, iNOS, ICAM-1expession, phosphorylation of CaMKII, and NF- | Li, 2016 |
| Curcumin |
| Alloxan-induced DR in rats and RGC from diabetic and normal rats | 100 mg/kg/day (in vivo); 10–1000 nmol/mL (in vitro) | In vivo and in vitro | ↓ Retinal inflammation, oxidative stress, retinal capillary basement membrane thickness, phosphorylation p65subunit of NF- | Pradhan, 2018 |
| Curcumin | — | STZ-induced PDR Wistar rat | 100 and 200 mg/kg/day (oral) | In vivo | ↓ Retinal angiogenesis, oxidative stress, apoptosis, retinal capillary basement membrane thickness, VEGF, and MDA ↑ Ratio of Bcl-2 to Bax, SOD, and T-AOC | Yang, 2018 |
| Curcumin | — | HG-induced ARPE-19 cells | 0–20 | In vitro | ↓ TNF- | Ran, 2019 |
| Curcumolide |
| STZ-induced DR, Wistar rats, and TNF-a-stimulated HUVECs | 2.5–20 | In vivo and in vitro | ↓ Retinal inflammation, leukostasis, vascular permeability, TNF-a, ICAM-1, p38 MAPK, and NF- | Cai, 2017 |
| Decursin |
| HRMVEC cells and STZ-induced SD rats | 20 mg/kg/day (oral); 12.5–100 | In vivo and in vitro | ↓ Retinal proliferation and angiogenesis, VEGFR-2 expression, tube formation, and retinal neovascularization | Yang, 2013 |
| (1) Docosahexaenoic acid | — | STZ-induced DR male Wistar rats | (1) CL and DL groups: 0.5 mg/kg (oral) | In vivo | (1) ↓ MDA (1,2) and nitrotyrosine level | Arnal, 2009 |
| Eriodictyol | — | HG-induced rat RGCs | 5–20 | In vitro | ↓ Retinal inflammation, production of ROS, TNF- | Lv, 2019 |
| Formononetin |
| ARPE-19 cells under chemical hypoxia and OIR model rats | 5.0 and 10.0 mg/kg/day (intraperitoneal); 0.2–5 | In vivo and in vitro | ↓ Retinal neovascularization, VEGF, HIF-1 | Wu, 2016 |
| Gastrodin |
| HG-induced HRECs | 0.1–10 and 100 | In vitro | ↓ TLR4/NF- | Zhang, 2018 |
| Genistein | — | ARPE-19 cells treated with normal and high glucose concentrations | 20 | In vitro | ↓ Retinal inflammation, angiogenesis, ALR, VEGF165, and VEGF secretion | Dongare, 2015 |
| Genistein combined polysaccharides | — | 12 postmenopausal Korean women | (Tablets) 2 g containing 120 mg of genistein and 57 mg of daidzein | In vivo | ↑ SHBG and GSH-Px activity | Oh, 2005 |
| Gentiopicroside | — | STZ-induced DR rats and rMC1 cells | 20–80 mg/kg/day; 10–100 | In vivo and in vitro | ↓ Retinal inflammation, oxidative stress, overexpression of HDAC, ROS expression, MDA, protein carbonyl expression, NF- | Zhang, 2019 |
| Hesperetin | — | STZ-induced DR Wistar rats | 200 mg/kg/day (oral) | In vivo | ↓ Retinal angiogenesis, dilated vessels, VEGF, PKC- | Kumar, 2012 |
| Hesperetin | — | STZ-induced DR Wistar albino rats | 100 mg/kg body (oral) | In vivo | ↓ Retinal inflammation, ROS, TNF- | Kumar, 2013 |
| Hesperidin | — | STZ-induced DR SD rats | 100 and 200 mg/kg/day (intragastrically) | In vivo | ↓ Retinal angiogenesis, oxidative stress, inflammation, permeability of the BRB, VEGF, ICAM-1, TNF- | Shi, 2012 |
| Kaempferol | — | HRECs under high glucose condition | 5–25 | In vitro | ↓ Retinal angiogenesis, proliferative ability, migration, VEGF and PGF expression, expression of PI3K, activation of Erk1/2, Src, and Akt1 | Xu, 2017 |
| Lithospermic acid B |
| OLETF rats | 10 or 20 mg/kg/day (oral) | In vivo | ↑ Thickness of the nerve layer, ganglion cells, and capillary BM layer ↓ VEGF, hsCRP, MCP1, TNF- | Jin, 2014 |
| Naringin | — | rMC1 STZ-induced DR rats | 20–80 mg/kg/day (intraperitoneally); 50 | In vivo and in vitro | ↓ Retinal inflammation, oxidative stress, TNF- | Liu, 2017 |
| Paeoniflorin | — | Microglia BV-2 cells and STZ-induced DR CD-1 mice | 20 and 40 mg/kg/day (oral); 0.1–10 | In vivo and in vitro | ↓ Retinal inflammation, MMP-9 activation, expression of p-p38, NF- | Zhu, 2017 |
| Physcion 8-O-Β-glucopyranoside | — | HG-disposed APRE-19 cell injury | 1.5 | In vitro | ↓ TNF- | Wan, 2020 |
| Pterostilbene | — | HRECs under high glucose environment | 1 mmol/l | In vitro | ↓ TNF- | Shen, 2015 |
| Puerarin | — | AGE-RSA induced bovine retinal pericyte cells AGE-RSA injected to rat eyes | 1, 5, and 10 | In vivo | ↓ NADPH oxidase activity, ROS, phosphorylation of p47 phox and Rac1, NF- | Kim, 2012 |
| Quercetin | — | ARPE-19 cells were stimulated by high glucose | 30 | In vitro | ↓ Cell apoptosis, MCP-1, IL-6, ROS, PTEN, p-p65, and I | Wang, 2020 |
| Resveratrol (trans-3,5,40-trihydroxystilbene) | — | STZ-induced DR rats | 5 mg/kg per day orally | In vivo | ↓ Retinal inflammation, NF- | Ghadiri Soufi, 2015 |
| Sauchinone | — | Human RPE cell line/ARPE-19 | 5, 10, and 20 | In vitro | ↑ SOD, GPX, CAT, Bcl-2, P-Akt, nuclear nrf2, HO-1, and Akt/nrf2/HO-1 signaling pathway ↓ ROS and Bax | Shi, 2019 |
| Scutellarin |
| HRECs under high glucose and hypoxic condition | 0.1 nM; 1 | In vitro | ↓ Retinal angiogenesis and proliferation, tube formation, HIF-1 | Wang, 2014 |
| Scutellarin | — | HRECs under high glucose and hypoxic condition and STZ-induced DR | 40 mg/kg/day (intragastrically); 10 | In vivo and in vitro | ↓ Retinal angiogenesis and proliferation, VEGF, phosphorylation of ERK, FAK, and Src | Long, 2019 |
| Sesamin | — | STZ-induced DR mice | 30 mg/kg BW (intraperitoneally), alternate day | In vivo | ↓ Retinal inflammation, TNF- | Ahmad, 2016 |
| Shikonin | — | STZ with whole-body hypoxia-induced DR in C57BL/6 mice and RPE cells | 0.5–50 mg/kg/day (oral); 0.1–10 | In vivo and in vitro | ↓ Retinal inflammation, vascular permeability, cell loss, COX-2, iNOS, Bax, MPO, and ZO-1 | Liao, 2017 |
| Silybin | — | STZ-induced DR SD rats | 15 and 30 mg/kg/day (orally) | In vivo | ↓ Retinal inflammation, obliterated retinal capillaries, retinal vascular leukostasis, and ICAM-1 | Zhang, 2014 |
| Sinomenine |
| Retinal microglia cells isolated from SD rats | 0.01–1 mM | In vitro | ↓ Retinal inflammation, microglial activation, IL-1 | Wang, 2007 |
| Sulforaphane | — | STZ-induced DR SD rats and rMC1 | 0.5 and 1 mg/kg/day 2.5 | In vivo and in vitro | ↓ Retinal inflammation, TNF- | Li, 2019 |
| Taxifolin | — | Alloxan-induced DR and albino Wistar male rats | 50 mg/kg/day (oral) | In vivo | ↓ Retinal inflammation, MDA, IL-1 | Ahiskali, 2019 |
| Zerumbone |
| STZ-induced DR and male Wistar rats | 40 mg/kg once a day orally | In vivo | ↓ Retinal inflammation, NF- | Tzeng, 2016 |
↓: decrease; ↑: increase.
Figure 1An insight into the molecular mechanism of angiogenesis, inflammation, and oxidative stress in the pathophysiology of diabetic retinopathy.
Figure 2Simultaneous and individual effects of phytochemicals on angiogenesis, inflammation, and oxidative stress in diabetic retinopathy.